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Breast magnetic resonance imaging (MRI) is indisputably the highest sensitivity test available to detect breast cancer, revealing more
extensive cancer in the ipsilateral and otherwise occult cancer in the contralateral breasts when used before surgery. The use of preoperative
breast MRI has become somewhat controversial, because the clinical benefit of the heightened detection provided by MRI has been ques-
tioned in the context of multidisciplinary breast cancer treatment, relatively low local recurrence, and metachronous contralateral cancer
rates. Also, MRI detection rates have been compared with the high rates reported in the pathology literature. The emerging clinical outcome
literature is showing conflicting results to demonstrating actual overall benefit. Critical review of this literature reveals several miscon-
ceptions about MRI detection rates and limitations of many of the published outcome studies to date, which render the results not necessarily
generalizable to contemporary optimized breast MRI practices. This article addresses some of the misconceptions raised by critics, provides
a critical review of the clinical outcome literature, reviews patient subgroups anticipated to have the highest yield when using preoperative
MRI, makes recommendations for optimizing breast MRI practice, and suggests areas for potential future research.Resume
L’imagerie par resonance magnetique (IRM) mammaire est sans conteste l’examen offrant la meilleure detection du cancer du sein.
Realisee avant la chirurgie, l’IRM permet de reveler la presence d’un cancer plus etendu dans le sein ipsilateral et d’un cancer autrement
occulte dans le sein controlateral. L’utilisation de l’IRM mammaire preoperatoire est devenue quelque peu controversee en raison d’une
remise en question des avantages cliniques de la detection amelioree que procure l’IRM dans un contexte caracterise par un traitement
multidisciplinaire du cancer du sein et des taux de recurrence locale et de cancer controlateral asynchrone relativement bas. De plus, les taux
de detection a l’IRM ont ete compares aux taux eleves rapportes dans les ecrits de pathologie. On constate un courant de conclusions
contradictoires au sein des ecrits en ce qui a trait a la demonstration des avantages globaux reels de l’examen. L’analyse critique de cette
documentation revele plusieurs idees fausses au sujet des taux de detection a l’IRM ainsi que les limites d’un grand nombre d’ etudes
existantes. Par consequent, les resultats ne peuvent pas necessairement e^tre generalises aux pratiques actuelles optimisees en matiere d’IRM
mammaire. Le present article traite de certaines des idees fausses relevees par les critiques, donne un compte rendu critique de la docu-
mentation sur les resultats cliniques, presente une analyse des sous-groupes de patientes susceptibles d’obtenir le meilleur rendement a l’IRM
preoperatoire, formule des recommandations pour optimiser la pratique de l’IRM mammaire et suggere des pistes de recherche futures.
 2011 Canadian Association of Radiologists. All rights reserved.
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on the global scale for more than 20 years; its use has more
dramatically increased over the last 10 years. It is indisputably
the highest sensitivity test available to detect breast cancer,
revealing more extensive cancer in the ipsilateral and other-
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women with breast cancer. In a meta-analysis of 19 studies
evaluating breast MRI in the preoperative setting, MRI
detected otherwise occult cancer in the ipsilateral breast in
11.1% of cases [1]. In a meta-analysis of 22 studies evaluating
detection in the contralateral breast at the time of diagnosis,
MRI found an additional 4.1% of cancers compared with
mammographywith orwithout the use of ultrasound, similar to
findings in a large multicentre prospective trial of an added
3.1% cancer detection rate [2,3]. In the preoperative setting,ll rights reserved.
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detection are as follows:
1. improved surgical planning that results in decreased
reoperation rates and better stratification of patients suited
to breast conserving surgery (BCS) vs mastectomy
2. decrease in breast recurrence rates by resecting otherwise
occult multifocal and/or multicentric tumour
3. decreased metachronous contralateral cancer rates by
simultaneous detection and treatment at the time of index
cancer treatment.
In the context of multidisciplinary breast cancer treatment
and relatively low rates of local recurrence, estimated at
5%e11%, the added value of MRI has come into question
[4,5]. As the clinical outcome literature begins emerging, the
use of breast MRI for preoperative staging is proving not to
be a straightforward issue. The aims of this article are to
review theoretically posed arguments against preoperative
breast MRI, outcome literature that addressed the proposed
benefits and claims of potential harms caused, requirements
for an optimized breast MRI practice, recommendations for
use, and directions for future investigation.
Theoretical Arguments Against Clinical Benefit
Pathology studies of whole breast specimens have estab-
lished that additional cancer foci are often present in the breast
diagnosedwith cancer, atmuchgreater rates than that diagnosed
before surgery by using Mx and clinical breast examination
(CBE). It is argued that the higher cancer detection rate by using
breast MRI is also much greater than breast recurrence rates
after BCS and modern adjuvant therapies, and this leads to
surgical overtreatment of biologically irrelevant cancer foci that
would otherwise be treated with adjuvant therapies.
However, although the extent of disease detected byMRI in
the ipsilateral breast closer approximates the levels reported in
pathology studies compared with standard imaging and CBE,
it does not reach these high levels. Furthermore, the MRI
detection rate is closer to recurrence rates than detection rates
based on pathologic assessment. A meta-analysis of studies
that investigated preoperative breast MRI in patients with
a diagnosed index cancer reported MRI detected additional
ipsilateral disease, including false-positive examinations, in
16% (range, 6%e34%) of patients. The cancer detection rate
of additional histologically proven multifocal or multicentric
cancer reported was 11.3% [1]. Pathology studies have
reported the presence of Mx and clinically occult additional
cancer foci in 21%e63%of cases [6e9]. By usingmastectomy
specimen pathology as a reference standard, Sardanelli et al
[10] reported that MRI had a lower false negative rate for
detecting all cancer foci in patients with a diagnosed breast
cancer, compared with Mx (19% [36/188] vs 34% [64/188]).
Also, the cancer focimissed by breastMRIwere smaller (mean
size, 5 mm), with a more favorable ratio of invasive-to-
noninvasive foci, compared with Mx, (mean size, 5 mm vs
8 mm; 1:1 vs 2.5:1) [10].The clinical benefit of contralateral breast cancer detection
has also been questioned. It is argued that the increased
contralateral cancer detection rate when using MRI is greater
than the metachronous cancer rate at follow-up. Because
invasive ipsilateral cancers are usually treated with systemic
therapies, eradication of existing but undetected contralateral
cancer is anticipated. Support of this theory comes from data
published by the Early Breast Cancer Trialists’ Collaborative
Group in an overview of the randomized clinical trials. They
found that, at a 15-year follow-up, the contralateral cancer rate
was reduced by 50% after 5 years of tamoxifen and by 20% in
patients who received adjuvant chemotherapy [11,12].
In a meta-analysis of the studies that evaluated MRI added
detection of contralateral cancer, the MRI contralateral
detection rate at the time of cancer diagnosis was 4% [2].
The 10-year cumulative incident rates of metachronous
contralateral cancers are reported at less than 5%, and 5-year
rates at 3% [13e15]. The synchronous cancer detection rate
of 4% is similar to the 5-year rate of 3% and arguably can
decrease this more relevant shorter follow-up metachronous
rate. In a meta-analysis of the data, Brennan et al [2] found
the false-negative rate of breast MRI in the contralateral
breast for the subset of patients undergoing prophylactic
mastectomy to be 12%. Similar to the findings in the
ipsilateral breast when using mastectomy specimen as the
criterion standard, MRI does not detect all cancer foci,
arguably missing those most likely to remain subclinical.
The concept that MRI is not simply identifying all cancer
present akin to pathology studies but rather can serve as an in
vivo biomarker of tumour biological significance has been
raised. Jansen et al [16] published their results on the
physiologic basis of ductal carcinoma in situ (DCIS)
enhancement when using a murine model. Because the
gadolinium was found within the lumens of neoplastic ducts,
they postulated that the gadolinium reached the lumen by
diffusing out of the capillaries into the extravascular space,
through leaky basement membranes of the ducts, damaged
by proteases secreted by the neoplastic cells. They further
hypothesized that the resulting leakiness of the basement
membrane may prove an important biomarker of a lesion’s
likelihood of becoming invasive [16]. In the follow-up
commentary, Kuhl [17] further postulates that DCIS detec-
ted on high-quality MRI provides more prognostically
relevant information than that detected on Mx, which is
based on calcifications caused by regressive tumour changes.
Results of Clinical Outcome StudiesMargins: Reoperation RatesThe comparative effectiveness of MRI in breast cancer
(COMICE) trial is the first randomized control trial (RCT) to
evaluate reoperation rates for breast cancer in groups of women
that did and did not undergo preoperative breast MRI. The trial
was performed between 2001 and 2007 and enrolled more than
1600 patients in 45 centres. It was designed to determine if
patients undergoing preoperative breast MRI experience better
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for positive margins. Turnbull et al [18] reported no change in
reoperation rates, which occurred in 19% of both groups
undergoing breastMRI in addition to standard triple assessment
(CBE, imaging with Mx and US, depending on the institution
recruiting and percutaneous needle sampling) compared with
those randomized to noMRI and concluded therewas no benefit
to adding preoperative breast MRI.
A similar failure to decrease reoperation rates for patients
diagnosed with invasive breast cancer ultimately excised to
negative margins on BCS was published by Hwang et al [19]
from University Health Network in Toronto on retrospective
review of 472 initially planned lumpectomies between 1999
and 2005. The investigators found similar reoperation rates
for the MRI group (11.3%) compared with the group not
undergoing MRI (13.3%) (P ¼ .5) [19].
Because RCTs are considered the most rigorous criterion
standard of study designs, being a RCT, COMICE is seem-
ingly an ideal study to answer the question: ‘‘Does preop-
erative breast MRI reduce reoperation rates?’’ Although the
RCT design eliminates some means of bias against MRI,
inherent in observational retrospective studies as will be
discussed later; COMICE introduced different forms of bias
against MRI. To recruit the number of patients required in
a reasonable time frame, the number of centres that partici-
pated was high (45 centres), which likely introduced a broad
spectrum of breast MRI experience and recruitment capa-
bilities. Based on the internal quality-assurance assessment,
8% of the examinations were technically noncompliant in the
study, most from low-recruitment centres [18]. Addressing
the importance of experience required for breast MRI inter-
pretation in a single institution study, Warner et al [20]
reported that the ability to detect DCIS by MRI in a high-
risk screening study, significantly improved with radiologist
experience. Because the COMICE trial found a lower
contralateral cancer detection rate of 1.6%, compared with
the American College of Radiology Imaging Network
(ACRIN) 6667 multicentre trial rate of 3.1% and the 4.1%
reported by Brennan et al [2] in a meta-analysis of pooled
data, this may indicate inferior technical and interpretive
factors compared with contemporary best practice [3,18].
To interpret the results of these studies, wemust understand
the study limitations that render them nongeneralizable.
Because the end point in the Toronto study was reoperation
rates to a point of breast conservation only, excluding patients
requiring repeated operation to mastectomy, a significant
number of relevant patients in the equation of improving
reoperation rates were likely excluded. Also, the potential
benefits MRI may provide, such as how often MRI altered
surgical management, are not reported based on inclusion
criteria. Because this was a retrospective study, there is an
inherent bias against the MRI group, because patients who
typically undergo MRI clinically typically have a higher
likelihood for more extensiveMx occult disease because of the
high risk and high breast density.
In the Toronto study and the many centres in the COMICE
trial, preoperative US staging was used rigorously before MRIstaging, which limited their results in the context of the MRI
practice in the same centres. During the time frame the studies
were conducted, there was very limited if any MRI-guided
biopsy, relying on post-MRI directed US for biopsy guid-
ance. The anticipated yield of additional cancer detection on
a second-look US is very low in the context of an initial US
negative examination. As a result, little expected benefit is to
be derived from breast MRI in practices that also use US
staging but without MRI-guided biopsy. Consequently, the
results can apply only to practices with preoperative breast
MRI in the context as they were used in these studies.
Furthermore, reference to multidisciplinary discussions on
altered plans of management based on MRI findings was not
made in either study.Given the complexmultitude of images to
review and interpret, the translation of the MRI-based infor-
mation to the surgeon is equally as critical as the interpretation.
The potential success of preoperative breast MRI hinges on
this relayed information and could also account for the lack of
decreasing reoperation rates in both studies.
Outcome data that supported breast MRI come from Mann
et al [21] in their retrospective study performed in 2 highly
experienced MRI centres. They included all consecutive
patients diagnosed with invasive lobular carcinoma and
compared reoperation and final mastectomy rates between 2
groups: patients who did and did not receive preoperative
breast MRI. The investigators reported that the re-excision
rates were reduced in patients who underwent breast MRI
(9%) compared with those who did not (27%) (P ¼ .010) and
found that there was a trend towards a decreased mastectomy
rate (48%) in the group that underwentMRI comparedwith the
group that did not (59%) (P¼ .098) [21]. Importantly, how this
study differs from the COMICE trial and the Toronto study is
the fact that patients were discussed and treatment plans were
devised by a multidisciplinary team of breast cancer special-
ists. Also, the centres are highly experienced at MRI-guided
biopsy, and MRI findings required pathology proof before
altering management, either by MRI-directed US if the lesion
was visible, or by biopsy using MRI guidance [22].
Finally, assessing reoperation rates as an end point in isola-
tion is complicated, because surgical oncology practices evolve
with time, and the goals themselves are not standardized. For
instance, the quality-assurance standard for the UK National
Health Service Breast Screening Programme set a goal of
reducing the reoperation rate for positivemargins to under 10%,
which can be achieved by very wide excisions at the expense of
cosmesis [18]. In her Lancet commentary, Morris [23]
addressed the problem created by the lack of standardized
goals across centres. Higher reoperation rates, approximating
25%, are acceptable in her centre as the surgeons attempt to
optimize cosmesis by limiting normal tissue excision.Mastectomy Rates IncreasedThe argument that breast MRI can lead to surgical over-
treatment of biologically irrelevant cancer, in the context of
adjuvant radiation and systemic therapies, is made by studies
that link increasing mastectomy rates to use of breast MRI.
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Clinic, Katipamula et al [24] reported on the trends of
mastectomy rates relative to periods before and after use of
preoperative breast MRI. They found that, after an initial
decline in overall rates from 45% in 1997 to 31% in 2003,
the rates then increased to as high as 45% by 2006. During
the time frame 2003-2006, the use of MRI more than
doubled, from 10% to 23%. Although patients who under-
went MRI were more likely to undergo mastectomy (54% vs
36%, P < .0001), the rate within this group remained rela-
tively stable. However, the mastectomy rate significantly
increased in the group that did not receive MRI (29%e41%,
P < .001) over the same time frame [24]. Inherent in this
retrospective study design, again, is a selection bias,
concentrating the patients who are more likely at the highest
risk for more extensive disease into the MRI group and,
therefore, are more likely to undergo mastectomy. Interest-
ingly, they found the highest increase in mastectomy rates in
patients not undergoing breast MRI, which underscored the
multifactorial reasons behind patients who chose mastec-
tomy. Irrespective of the extent of cancer, patient factors
found to be associated with increased likelihood of mastec-
tomy include higher education level, younger age, and those
offered immediate reconstruction [25,26].False Positives: Increased Surgery Based on False
PositivesPreoperative breast MRI has been criticized for causing
pathologically unnecessary more-extensive surgery than
initially planned based on false-positive findings. In a meta-
analysis of preoperative breast MRI studies, Houssami et al
[1] found that more extensive surgery was performed based on
false-positive MRI findings (ie, MRI detected suspicious but
not biopsy confirmed lesions), including conversion from
lumpectomy to wider excision in 4.4% and from lumpectomy
tomastectomy in 1.1% of cases [1]. In the COMICE trial, 38%
of patients whose surgery was converted to mastectomy based
on MRI findings were because of false-positive findings [18].
This is important and is hoped to be historical information,
which emphasizes the need for changes in surgical manage-
ment to be based on biopsy proof ofmore extensive disease and
not only on imaging findings. Because many of these studies
were performed before any or ready availability of MRI-
guided biopsy, the results are acceptable to practice stan-
dards within the study time frames. However, in contemporary
practice, breastMRIwithMRI-guided biopsy available should
not account for such pathologically unnecessary surgery,
because this practice is no longer justifiable.Recurrence RatesData that evaluated proposed relationships between use of
breast MRI and local recurrence rates have recently emerged.
In a retrospective review that assessed recurrence rates after
breast conserving treatment for early stage breast cancer in
patients treated between 1992e2001, Solin et al [27]reported no change in local recurrence rates at an 8-year
follow-up, including a 3% rate for those patients who
underwent breast MRI compared with 4% in those patients
who did not (P ¼ .51) [27]. However, only half of the MRI
examinations were actually performed before surgery, the
remaining half were after lumpectomy or after repeated re-
excision, which is most often performed for positive
margins. Not only does this enrich the MRI group to those
more likely to recur based on margin status but introduces
a greater diagnostic challenge for image interpretation
unique to the postoperative setting compared with preoper-
ative imaging.
Similarly, no difference in local recurrence rates was
reported by Hwang et al [19] in a retrospective review of
patients diagnosed with invasive breast cancer ultimately
excised to negative margins on BCS, over a short follow-up
time, median 54 months (range, 4.8e111.6 months). They
found similar actuarial 8-year recurrence rates, 1.8% for the
group undergoing MRI compared with 2.5% for those who
did not (P ¼ .67) [19]. Whereas all breast MRI examinations
included in this study were performed before surgery, in
contrast to the study by Solin, both studies had many similar
limitations, which must be understood to interpret the results
and recognize their nongeneralizable nature [18,27]. The
benefit of MRI is likely to be underestimated in both studies,
based on the inclusion criteria; excluding patients who
required mastectomy for MRI detected extensive disease.
Breast MRI was in its early stages during the time frame of
both studies, and many advances have been made both
technologically and interpretively. The recognition of more
subtle appearances of cancer, including non-mass lesions,
were beginning to be published in the last year (2001) of the
Solin study [28,29]. During the study time frames, the group
at the University of Pennsylvania had much experience with
MRI-guided wire localization and surgical biopsy, but
MRI-guided percutaneous biopsy was just beginning, and
little if any MRI-guided intervention was performed in the
Toronto study [19,27]. Based on the retrospective design of
both studies, patients at higher risk are more likely to be
recommended for MRI and, therefore, included in the MRI
arm.
One study that demonstrated a positive impact of MRI on
recurrence rates comes from Fischer et al [30] in a retro-
spective review of patients diagnosed with breast cancer
from 1993e1997. They found a significantly lower recur-
rence rate of 1.2% in those patients who underwent preop-
erative breast MRI compared with 6.8% for those patients
who did not (P < .001), at a minimum of a 20-month follow-
up (mean, 40.3 months). Use of MRI-guided wire localiza-
tion and surgical biopsy was used as outlined during the time
of this study to verify MRI-only visible suspicious lesions.
This study recorded final breast surgical outcome, including
a higher mastectomy rate, of 39% compared with 29% for
those patients who did not undergo breast MRI. Despite the
retrospective nature and early time frame of this study,
a decrease in recurrence rates was demonstrated. This study
has been criticized, however, for potential biases against the
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tumour characteristics, and adjuvant systemic therapies. The
relatively high local recurrence rate for the non-MRI group
compared with contemporary practices at such a short
follow-up interval is another criticism against its generaliz-
ability. Despite providing end surgical outcome rates of
mastectomy or BCS for the 2 groups, the rates of altering
surgical planning based on MRI findings was not provided.Metachronous Contralateral Breast Cancer RatesThere is little clinical outcome data on breast MRI’s
ability to decrease the metachronous contralateral breast
cancer rate. Detection of synchronous contralateral cancer is
anticipated to affect rates at a relatively shorter follow-up
period (about 1e5 years). The data available come from
studies whose primary aims were evaluating ipsilateral breast
recurrence rates between groups of patients who did and did
not receive pre- or perioperative MRI. Fischer et al [30]
published the only study that addressed the timing of
contralateral cancer presentation and found a decreased rate
of metachronous cancers in the MRI group compared with
the no-MRI group (1.7% vs 4%, P < .001). The follow-up
period was 14e52 months (mean, 35 month) [30].
Solin et al [27] found no difference in the contralateral
breast cancer rates at 8 years, 6% in both groups, but does
not provide details about the timing of detection to determine
if MRI affects metachronous rates. The average follow-up
period in this study was 4.6 years but ranged from as low
as 0.1 year to 13.5 years. However, during a shorter follow-
up period, of 5 years, relevant to address this question, the
detection rate in the MRI group was only 3% compared with
6% in the non-MRI group, which suggests that MRI may
have had some effect in lowering metachronous contralateral
cancer rates in this patient population [27].
Optimizing Breast MRI Practice
It is apparent across all of the studies that evaluated preop-
erative breastMRI that the clinical outcome results can only be
as good as the manner in which breast MRI is practiced. The
results of studies that evaluated MRI during its early period or
more recent studies, including practices in which breast MRI
practice was not optimized and lack of MRI-guided biopsy
capability are not generalizable to contemporary best breast
MRI practice. The American College of Radiology (ACR) has
published practice guidelines and technical standards that
outline the basic minimum equipment and protocol require-
ments [31]. TheACR is launching its accreditation program for
breast MRI, similar to that established forMx and breast US, in
attempt to ensure quality control and quality assurance for
participating centres. Importantly, in the United States,
accreditation will be required for reimbursement by Medicare
for breast MRI examinations. One of the criteria required for
accreditation will be MRI-guided biopsy capability or estab-
lishing a referral arrangement for MRI-guided biopsy with
a cooperating facility.Recommendations for Use
Recommended guidelines for using preoperative breast
MRI have been published, developed to encompass those
groups for whom MRI is anticipated to provide the highest
diagnostic yield, based on limitations of mammographic
sensitivity and highest pretest risk for the presence of
multifocal and/or multicentric and contralateral cancer
[1,32]. Groups for whom preoperative breast MRI has been
recommended based on highest anticipated yield are as
follows:
1. mammographically dense breasts
2. known multifocal/multicentric disease or bilateral cancer
3. invasive lobular cancer
4. high risk for hereditary breast cancer
5. partial breast irradiation candidate
However, any individual patient with a recent diagnosis of
breast cancer can potentially benefit from preoperative breast
MRI through the detection of otherwise occult cancer foci in
the ipsilateral and contralateral breasts. Whereas Mx sensi-
tivity worsens with greater breast density, breast density alone
is not a perfect indicator of who will benefit from breast MRI.
Lehman et al [3] found no difference in detection rates of Mx
occult cancer in the contralateral breast when using MRI,
based on breast density, with equal detection rates of 3% for
fatty and dense breasts. In the context of screening women at
high risk, Bigenwald et al [33] found, by using the Breast
Imaging Reporting and Data System (BI-RADS) density
classification, that whereas Mx sensitivity was slightly higher
for low-density breasts (<50% density) compared with high-
density breasts (>50% density), it was poor when compared
with MRI. The reported Mx sensitivity for low-density breasts
was 33%, compared with 94% for MRI and 18% for high
breast density compared with 86% for MRI [33].
Lehman et al [3] also found other factors, including
histology of the index cancer and menopausal status, were
not predictors of diagnostic yield for detecting contralateral
breast cancer with MRI. However, in the context of limited
MRI resources available, individual practices may or may
not choose to adopt guidelines based on highest anticipated
yield of cancer detection.
Conclusions and Future Directions
On critical review of the preoperative breast MRI clinical
outcome literature, it is apparent that the results are not
generalizable but can be applied to programs that practice
breast MRI in a manner similar to those in the published
studies. The results do highlight the need for quality control
and assurance in a breast MRI program to include MRI-
guided biopsy capability and a multidisciplinary approach
to manage patients by incorporating the MRI results.
Within the context of an optimized breast MRI practice,
continued investigation on how to best translate the extent of
cancer information to the surgeon in the operating room
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cosmesis. Some strategies being explored include supine
breast MRI and preoperative mapping techniques that
involve prone MRI-guided wire localization and combined
US and MRI mapping with the patient in the supine position
[34,35].
Because there is no outcome data that stratify patient
subgroups based on demonstrated benefit from preoperative
breast MRI, future investigation is warranted. Data that link
tumour biomarkers to outcomes such as recurrence risk and
death from breast cancer are available and should be
considered in future studies that look at benefits of preop-
erative MRI [36e39]. The MRI identification of tumours that
could otherwise be untreated in the context of emerging
targeted therapies in medical and radiation oncology is an
area for potential investigation. One such therapeutic
approach is the use of breast tumour multigene assays to
personalize patient treatment according to risk for relapse by
identifying patients likely to benefit or not from adjuvant
chemotherapy. Another targeted therapy is the use of accel-
erated partial-breast irradiation (APBI) as an alternative to
whole-breast irradiation, a technique that treats a limited
volume of tissue around the lumpectomy site, significantly
decreasing the dose to ‘‘uninvolved’’ breast and surrounding
organs. Studies that evaluated preoperative breast MRI in
candidates for APBI found that 6%-10% of patients had
additional cancer foci detected by MRI that would not have
been resected at initially planned lumpectomy planned on
Mx, with or without US and CBE, nor treated with APBI
[40,41].
Whereas breast MRI has been criticized for leading to
surgical overtreatment, it is well recognized that, despite the
known morbidities associated with radiation, many patients
are likely overtreated with radiation when using conventional
criteria for candidacy. By taking advantage of the high
negative predictive value of MRI, it is conceivable that breast
radiation can be avoided for certain subtypes of cancer if no
additional disease is confirmed on high-quality MRI, an area
that potentially warrants investigation.
Lastly, the preoperative breast MRI clinical outcome
literature to date is conflicting to demonstrating benefit or
not. It is apparent that more studies are necessary, ideally that
involve breast MRI practices in more contemporary time
periods, performing MRI at an ACR accreditation level, in
a multidisciplinary setting. Ideally, future studies will be
radiologist led or at least have significant input into study
design from experienced radiologists familiar with the many
variables that affect breast MRI.References
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